Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens.

Autor:	Baden D; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; University Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel. david.baden@uksh.de., Zukunft S; Medical Department I, University Hospital of TU Dresden, Dresden., Hernandez G; TriNetX, TriNetX Europe NV, Sint-Martens-Latem., Wolgast N; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; University Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel., Steinhauser S; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; University Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel., Pohlmann A; Department of Medicine A, University Hospital Munster., Schliemann C; Department of Medicine A, University Hospital Munster., Mikesch JH; Department of Medicine A, University Hospital Munster., Steffen B; Medical Department II, J.-W.-Goethe University Hospital Frankfurt., Sauer T; Medical Department V, Heidelberg University Hospital., Hanoun M; Department of Hematology, Essen University Hospital., Schafer-Eckart K; Medical Department 5, University Hospital of Paracelsus Medical University Nuremberg., Krause SW; Department of Medicine 5, Uniklinikum Erlangen., Hanel M; Department for Internal Medicine III, Klinikum Chemnitz., Einsele H; Medical Department II, University Hospital Wurzburg., Jost E; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany and Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Dusseldorf (ABCD), Aachen., Brummendorf TH; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany and Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Dusseldorf (ABCD), Aachen., Scholl S; Klinik fur Innere Medizin II, Jena University Hospital, Jena., Hochhaus A; Klinik fur Innere Medizin II, Jena University Hospital, Jena., Neubauer A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg., Burchert A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg., Kaufmann M; Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch-Hospital Stuttgart., Niemann D; Internal Medicine, Hematology/Oncology, Palliative Medicine, Gemeinschaftsklinikum Mittelrhein, Koblenz., Schaich M; Department for Hematology, Oncology and Palliative Medicine, Rems-Murr-Klinikum, Winnenden., Blau W; Department for Internal Medicine III, Helios Dr Schmidt Hospital Wiesbaden., Kiani A; Department for Oncology and Hematology, Klinikum Bayreuth, and Comprehensive Cancer Center Erlangen-EMN., Gorner M; Department for Hematology, Oncology and Palliative Medicine, Klinikum Bielefeld, Bielefeld., Kaiser U; Medical Department II, St. Bernward Hospital, Hildesheim., Kullmer J; Medical Department II, Hematology and Oncology, DIAKO Bremen., Weber T; Department for Internal Medicine IV, University Hospital Halle (Saale)., Berdel WE; Department of Medicine A, University Hospital Munster., Ehninger G; Medical Department I, University Hospital of TU Dresden, Dresden., Muller-Tidow C; Medical Department V, Heidelberg University Hospital., Platzbecker U; Medical Department I, Hematology and Cell Therapy, University Hospital Leipzig., Serve H; Medical Department II, J.-W.-Goethe University Hospital Frankfurt., Bornhauser M; Medical Department I, University Hospital of TU Dresden, Dresden., Rollig C; Medical Department I, University Hospital of TU Dresden, Dresden., Baldus CD; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; University Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel., Fransecky L; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany; University Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel.
Jazyk:	angličtina
Zdroj:	Haematologica [Haematologica] 2024 Aug 01; Vol. 109 (8), pp. 2469-2477. Date of Electronic Publication: 2024 Aug 01.
DOI:	10.3324/haematol.2024.285225
Abstrakt:	In newly diagnosed acute myeloid leukemia (AML), immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pretherapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagnosed AML undergoing venetoclax-based therapy in two distinct cohorts. By querying the Study Alliance Leukemia database and the global health network TriNetX, we identified 138 and 717 patients respectively with an average age of 76 and 72 years who received venetoclax-based first-line therapy. When comparing patients who started treatment earlier or later than 10 days after initial diagnosis, no significant difference in median overall survival was observed - neither in the SAL cohort (7.7 vs. 9.6 months; P=0.42) nor in the TriNetX cohort (7.5 vs. 7.2 months; P=0.41). Similarly, severe infections, bleeding, and thromboembolic events were equally observed between early and later treatments, both in the overall patient groups and specific subgroups (age ≥75 years or leukocytes ≥20x109/L). This retrospective analysis indicates that delaying the start of venetoclax-based therapy in newly diagnosed AML might be a safe option for selected patients, provided that close clinical monitoring is performed.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu